Novartis AG (Novartis AG) Long-Term Capital Lease Obligation

: $1,598 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Novartis AG's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,598 Mil.

Novartis AG's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($1,545 Mil) to Sep. 2023 ($1,453 Mil) but then increased from Sep. 2023 ($1,453 Mil) to Dec. 2023 ($1,598 Mil).

Novartis AG's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($1,621 Mil) to Dec. 2022 ($1,538 Mil) but then increased from Dec. 2022 ($1,538 Mil) to Dec. 2023 ($1,598 Mil).

Novartis AG Long-Term Capital Lease Obligation Historical Data

The historical data trend for Novartis AG's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

1,703.00

1,719.00

1,621.00

1,538.00

1,598.00

Novartis AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																1,538.00	1,589.00	1,545.00	1,453.00	1,598.00

Novartis AG (NYSE:NVS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Novartis AG Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Novartis AG's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NVSEF:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.